Lexicon Pharmaceuticals (LXRX) is back in focus after first quarter results showed revenue of US$21.1 million versus US$1.26 million a year earlier, along with a net loss of US$1.04 million compared with US$25.3 million.

The stock’s recent 1-day share price return fell 4.29% to US$2.23, while the 90-day share price return of 70.23% and 1-year total shareholder return of 316.67% indicate strong momentum following the earnings update, conference appearance, and new loan facility.

If this kind of turnaround story has your attention, it may be worth widening your search to other healthcare-related opportunities using our screener for 32 healthcare AI stocks

With revenue at US$69.6 million over the last year, a market cap near US$990.3 million, and the stock trading at US$2.23 versus a US$3.72 analyst target, is there still an opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 40.1% Undervalued

Lexicon Pharmaceuticals' most followed valuation narrative pegs fair value at $3.72 per share, well above the latest close at $2.23. That difference is what draws attention to the assumptions sitting underneath that gap.

In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 133.9x on those 2029 earnings, up from -32.5x today. This future PE is greater than the current PE for the US Pharmaceuticals industry at 16.1x.

Want to see why this narrative leans on brisk revenue growth, a swing to positive margins, and a premium earnings multiple to support that $3.72 figure? The full story connects clinical milestones, licensing economics, and dilution assumptions into one tight valuation case that is very different from what the current share price implies.

Result: Fair Value of $3.72 (UNDERVALUED)

However, this hinges heavily on pilavapadin and LX9851 progressing as hoped, and any setback in trials, approvals, or partnering could quickly weaken the undervalued argument.

Another Angle: Price To Sales Sends A Different Signal

While the fair value narrative points to upside, the current P/S of 14.2x is very high compared with the US Pharmaceuticals industry at 5.5x, peers at 7.1x, and even the fair ratio of 7.1x. That kind of gap raises a simple question for investors: is enthusiasm already running ahead of fundamentals?

To see how the numbers stack up side by side and what that means in practice, take a look at our valuation breakdown, which uses the P/S gap as a cross check on the analyst target, and then decide how much multiple risk you are comfortable carrying here, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Torn between the upbeat fair value story and the richer P/S signal, especially with both risks and rewards in play right now? Act while the facts are fresh and weigh those trade offs for yourself by reviewing the 1 key reward and 2 important warning signs

Looking for more investment ideas?

If Lexicon has sharpened your focus, do not stop here. Broaden your watchlist with other stocks that fit clear, focused criteria using the Simply Wall St screener.

• Target potential bargains by scanning for companies flagged as 51 high quality undervalued stocks that may offer more attractive pricing than their fundamentals suggest.
• Prioritise resilience by looking through 66 resilient stocks with low risk scores so you can concentrate on stocks with lower overall risk scores.
• Hunt for lesser known opportunities by checking the screener containing 21 high quality undiscovered gems before other investors start paying attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.